|
US6037323A
(en)
*
|
1997-09-29 |
2000-03-14 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6046166A
(en)
*
|
1997-09-29 |
2000-04-04 |
Jean-Louis Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
US6004925A
(en)
*
|
1997-09-29 |
1999-12-21 |
J. L. Dasseux |
Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
|
|
IL145712A0
(en)
*
|
1999-04-01 |
2002-07-25 |
Esperion Therapeutics Inc |
Ether compounds, compositions, and uses thereof
|
|
US7407663B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified immunodeficiency virus particles
|
|
US7439052B2
(en)
*
|
2000-06-29 |
2008-10-21 |
Lipid Sciences |
Method of making modified immunodeficiency virus particles
|
|
US7407662B2
(en)
|
2000-06-29 |
2008-08-05 |
Lipid Sciences, Inc. |
Modified viral particles with immunogenic properties and reduced lipid content
|
|
AUPQ846900A0
(en)
*
|
2000-06-29 |
2000-07-27 |
Aruba International Pty Ltd |
A vaccine
|
|
US20090017069A1
(en)
*
|
2000-06-29 |
2009-01-15 |
Lipid Sciences, Inc. |
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
US7148197B2
(en)
*
|
2000-08-24 |
2006-12-12 |
The Regents Of The University Of California |
Orally administered small peptides synergize statin activity
|
|
US7199102B2
(en)
*
|
2000-08-24 |
2007-04-03 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US8568766B2
(en)
|
2000-08-24 |
2013-10-29 |
Gattadahalli M. Anantharamaiah |
Peptides and peptide mimetics to treat pathologies associated with eye disease
|
|
US6664230B1
(en)
*
|
2000-08-24 |
2003-12-16 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
US7166578B2
(en)
*
|
2000-08-24 |
2007-01-23 |
The Regents Of The University Of California |
Orally administered peptides synergize statin activity
|
|
US7723303B2
(en)
*
|
2000-08-24 |
2010-05-25 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
AU2007237157B2
(en)
*
|
2000-08-24 |
2009-04-09 |
The Regents Of The University Of California |
Peptides that ameliorate atherosclerosis
|
|
US7144862B2
(en)
*
|
2000-08-24 |
2006-12-05 |
The Regents Of The University Of California |
Orally administered peptides to ameliorate atherosclerosis
|
|
DE10051983A1
(de)
*
|
2000-10-20 |
2002-06-13 |
Beate Kehrel |
Inhibierung der pathogenen Wirkung oxidierter Proteine
|
|
ES2429528T3
(es)
|
2001-01-02 |
2013-11-15 |
The Cleveland Clinic Foundation |
Mieloperoxidasa, un indicador de riesgo para enfermedad cardiovascular
|
|
US20050089932A1
(en)
*
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US7217785B2
(en)
*
|
2001-05-09 |
2007-05-15 |
The Regents Of The University Of California |
Cysteine-containing peptides having antioxidant properties
|
|
US6991727B2
(en)
*
|
2001-06-25 |
2006-01-31 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
US20060060520A1
(en)
*
|
2001-06-25 |
2006-03-23 |
Bomberger David C |
Systems and methods using a solvent for the removal of lipids from fluids
|
|
JP2004532709A
(ja)
*
|
2001-06-25 |
2004-10-28 |
リピド サイエンスィズ インコーポレイテッド |
流体から脂質を除去するための溶媒を用いたシステムおよび方法
|
|
EP1409108A4
(en)
*
|
2001-06-25 |
2007-11-14 |
Lipid Sciences Inc |
HOLLOW FIBER CONTACTOR SYSTEMS FOR THE REMOVAL OF LIPIDS FROM LIQUIDS
|
|
WO2003000381A1
(en)
|
2001-06-25 |
2003-01-03 |
Lipid Sciences, Inc. |
Hollow fiber contactor systems for removal of lipids from fluids
|
|
AU2002362612B2
(en)
*
|
2001-09-28 |
2007-11-15 |
Cedars-Sinai Medical Center |
Prevention and treatment of restenosis by local administration of drug
|
|
KR20040063901A
(ko)
*
|
2001-09-28 |
2004-07-14 |
에스페리온 테라피유틱스 인코포레이티드 |
고압에서 소포체를 압출하는 방법 및 장치
|
|
US20040009216A1
(en)
*
|
2002-04-05 |
2004-01-15 |
Rodrigueza Wendi V. |
Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
|
|
US6930085B2
(en)
*
|
2002-04-05 |
2005-08-16 |
The Regents Of The University Of California |
G-type peptides to ameliorate atherosclerosis
|
|
US20100204103A1
(en)
*
|
2002-05-08 |
2010-08-12 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
JP2006502976A
(ja)
*
|
2002-05-17 |
2006-01-26 |
エスペリオン セラピューティクス，インコーポレイテッド |
虚血再潅流を治療する方法および組成物
|
|
WO2003096983A2
(en)
*
|
2002-05-17 |
2003-11-27 |
Esperion Therapeutics, Inc. |
Method of treating dyslipidemic disorders
|
|
CA2494098A1
(en)
*
|
2002-07-30 |
2004-02-05 |
Esperion Therapeutics, Inc. |
Methods of using non-human animal apoliprotein a-i protein
|
|
JP2005538148A
(ja)
*
|
2002-08-26 |
2005-12-15 |
リピド サイエンスィズ インコーポレイテッド |
脱脂タンパク質粒子を使用したアルツハイマー病治療
|
|
EP2404890B1
(en)
*
|
2003-01-23 |
2017-07-26 |
Esperion Therapeutics Inc. |
Hydroxyl compounds and compositions for cholesterol management and related uses
|
|
AU2004233333A1
(en)
*
|
2003-04-22 |
2004-11-04 |
Avanir Pharmacueticals |
Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
|
|
US7375191B2
(en)
*
|
2003-07-03 |
2008-05-20 |
Lipid Science, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
US7393826B2
(en)
|
2003-07-03 |
2008-07-01 |
Lipid Sciences, Inc. |
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
US7459286B1
(en)
|
2003-10-22 |
2008-12-02 |
The Cleveland Clinic Foundation |
Assessing the risk of a major adverse cardiac event in patients with chest pain
|
|
US6960803B2
(en)
*
|
2003-10-23 |
2005-11-01 |
Silicon Storage Technology, Inc. |
Landing pad for use as a contact to a conductive spacer
|
|
US7781219B2
(en)
|
2003-12-05 |
2010-08-24 |
The Cleveland Clinic Foundation |
Risk markers for cardiovascular disease
|
|
CA2549529A1
(en)
*
|
2003-12-15 |
2005-06-30 |
The Regents Of The University Of California |
Helical synthetic peptides that stimulate cellular cholesterol efflux
|
|
WO2005068020A1
(en)
*
|
2004-01-02 |
2005-07-28 |
Advanced Cardiovascular Systems, Inc. |
High-density lipoprotein coated medical devices
|
|
US8926958B2
(en)
*
|
2004-04-06 |
2015-01-06 |
Cedars-Sinai Medical Center |
Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
|
|
US7378396B2
(en)
*
|
2004-08-11 |
2008-05-27 |
The Cleveland Clinic Foundation |
Therapeutic agents and methods for cardiovascular disease
|
|
AU2005287004B2
(en)
*
|
2004-09-16 |
2011-03-17 |
The Regents Of The University Of California |
G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
|
|
WO2006049597A1
(en)
*
|
2004-10-27 |
2006-05-11 |
Avanir Pharmaceuticals |
Amino acid-derived compounds as modulators of the reverse cholesterol transport
|
|
US7579319B2
(en)
|
2004-12-06 |
2009-08-25 |
The Regents Of The University Of California |
Methods for improving the structure and function of arterioles
|
|
US20060160721A1
(en)
*
|
2004-12-22 |
2006-07-20 |
Baylor College Of Medicine |
Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis
|
|
US7759315B2
(en)
|
2005-03-09 |
2010-07-20 |
Csl Behring Ag |
Treatment of inflammatory conditions of the intestine
|
|
US8206750B2
(en)
|
2005-03-24 |
2012-06-26 |
Cerenis Therapeutics Holding S.A. |
Charged lipoprotein complexes and their uses
|
|
KR20080007491A
(ko)
*
|
2005-04-29 |
2008-01-21 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
염증성 반응을 특징으로 하는 병리를 치료하기 위한 펩티드및 펩티드 모방체
|
|
US20080293639A1
(en)
*
|
2005-04-29 |
2008-11-27 |
The Regents Of The University Of California |
Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
|
|
EP1924262B1
(en)
*
|
2005-08-22 |
2011-11-16 |
Melior Pharmaceuticals I, Inc. |
Methods and formulations for modulating lyn kinase activity and treating related disorders
|
|
US20070254832A1
(en)
*
|
2006-02-17 |
2007-11-01 |
Pressler Milton L |
Methods for the treatment of macular degeneration and related eye conditions
|
|
CA2653840A1
(en)
*
|
2006-06-01 |
2007-12-06 |
Institut De Cardiologie De Montreal |
Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
|
|
US20080199398A1
(en)
*
|
2006-06-16 |
2008-08-21 |
Brewer H Bryan |
Novel Peptides That Promote Lipid Efflux
|
|
US20080227686A1
(en)
*
|
2006-06-16 |
2008-09-18 |
Lipid Sciences, Inc. |
Novel Peptides that Promote Lipid Efflux
|
|
US20080206142A1
(en)
*
|
2006-06-16 |
2008-08-28 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
AU2007284801A1
(en)
|
2006-08-08 |
2008-02-21 |
The Regents Of The University Of Californina |
Salicylanilides enhance oral delivery of therapeutic peptides
|
|
US20080138284A1
(en)
*
|
2006-09-26 |
2008-06-12 |
Lipid Sciences, Inc. |
Novel Peptides That Promote Lipid Efflux
|
|
US8541236B2
(en)
*
|
2006-12-08 |
2013-09-24 |
University Of Washington |
Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
|
|
WO2008094905A2
(en)
*
|
2007-01-29 |
2008-08-07 |
Lipid Sciences, Inc. |
Encapsulated hdl mimetic peptides
|
|
WO2008094939A1
(en)
*
|
2007-01-31 |
2008-08-07 |
Nutrition 21, Inc. |
Use of chromium histidinate for treatment of cardiometabolic disorders
|
|
CA2678813A1
(en)
*
|
2007-02-20 |
2008-08-28 |
Melior Pharmaceuticals I, Inc. |
Methods of identifying activators of lyn kinase
|
|
DK1964571T3
(da)
|
2007-03-01 |
2012-08-13 |
Csl Ltd |
Behandling af endothelial dysfunktion hos diabetespatienter
|
|
PL3050568T3
(pl)
|
2007-03-13 |
2021-06-14 |
Jds Therapeutics, Llc |
Sposoby i kompozycje do przedłużonego uwalniania chromu
|
|
WO2009002867A2
(en)
|
2007-06-26 |
2008-12-31 |
Nutrition 21, Inc. |
Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
|
|
US20100197710A1
(en)
*
|
2007-07-23 |
2010-08-05 |
Melior Pharmaceuticals I, Inc. |
Methods Of Activating IRS-1 And AKT
|
|
JP2010537638A
(ja)
|
2007-08-28 |
2010-12-09 |
ユーエービー リサーチ ファウンデーション |
合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
|
|
EP2682400B1
(en)
|
2007-08-28 |
2017-09-20 |
Uab Research Foundation |
Synthetic apolipoprotein E mimicking polypeptides and methods of use
|
|
US7985728B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US9173890B2
(en)
*
|
2007-09-20 |
2015-11-03 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US7985727B1
(en)
|
2007-09-20 |
2011-07-26 |
Abbott Cardiovascular Systems Inc. |
Apo A-I mimetic peptides and methods of treatment
|
|
US8101565B2
(en)
|
2007-09-20 |
2012-01-24 |
Abbott Cardiovascular Systems Inc. |
Sustained release of Apo A-I mimetic peptides and methods of treatment
|
|
US8044021B2
(en)
*
|
2007-09-20 |
2011-10-25 |
Abbott Cardiovascular Systems Inc. |
Sustained release of apo A-I mimetic peptides and methods of treatment
|
|
US8552184B2
(en)
*
|
2008-07-03 |
2013-10-08 |
Melior Pharmaceuticals I, Inc. |
Compounds and methods for treating disorders related to glucose metabolism
|
|
US8241861B1
(en)
|
2008-07-08 |
2012-08-14 |
Insilicos, Llc |
Methods and compositions for diagnosis or prognosis of cardiovascular disease
|
|
MX351819B
(es)
|
2008-11-10 |
2017-10-30 |
Alnylam Pharmaceuticals Inc |
Lipidos y composiciones novedosas para el suministro de terapeuticos.
|
|
CA2751342C
(en)
|
2009-01-29 |
2019-05-07 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
|
|
EP2939683B1
(en)
|
2009-02-16 |
2017-01-04 |
Cerenis Therapeutics Holding SA |
Apolipoprotein A-I Mimics
|
|
CA2754043A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
SG10201402054UA
(en)
|
2009-05-05 |
2014-09-26 |
Muthiah Manoharan |
Lipid compositions
|
|
PT3431076T
(pt)
|
2009-06-10 |
2021-10-26 |
Arbutus Biopharma Corp |
Formulação lipídica melhorada
|
|
EP2810643A3
(en)
|
2009-08-14 |
2015-03-11 |
Alnylam Pharmaceuticals Inc. |
Lipid formulated compositions and mehods for inhibiting expression of a gene from the ebola virus
|
|
US20120270771A1
(en)
*
|
2009-09-30 |
2012-10-25 |
Snu R&Db Foundation |
Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
|
|
US10894098B2
(en)
|
2012-04-09 |
2021-01-19 |
Signablok, Inc. |
Methods and compositions for targeted imaging
|
|
WO2011044545A2
(en)
|
2009-10-09 |
2011-04-14 |
Sigalov Alexander B |
Methods and compositions for targeted imaging
|
|
US12419839B2
(en)
|
2009-10-09 |
2025-09-23 |
Signablok, Inc. |
Methods and compositions for targeted delivery of protein fragments
|
|
CA3044884A1
(en)
|
2009-12-07 |
2011-06-16 |
Arbutus Biopharma Corporation |
Compositions for nucleic acid delivery
|
|
EP2512449B1
(en)
|
2009-12-18 |
2019-08-07 |
The University of British Columbia |
Methods and compositions for delivery of nucleic acids
|
|
WO2011139911A2
(en)
|
2010-04-29 |
2011-11-10 |
Isis Pharmaceuticals, Inc. |
Lipid formulated single stranded rna
|
|
WO2011143362A1
(en)
|
2010-05-11 |
2011-11-17 |
Esperion Therapeutics, Inc. |
Dimeric oxidation-resistant apolipoprotein a1 variants
|
|
WO2011150300A1
(en)
|
2010-05-28 |
2011-12-01 |
Melior Pharmaceuticals I, Inc. |
Prevention of pancreatic beta cell degeneration
|
|
JP5893611B2
(ja)
|
2010-06-03 |
2016-03-23 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
活性剤の送達のための生分解性脂質
|
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
|
WO2012016188A2
(en)
|
2010-07-30 |
2012-02-02 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
|
BR112013004397A2
(pt)
|
2010-08-30 |
2017-06-27 |
Hoffmann La Roche |
método para produzir uma partícula de lipídio, a partícula de lipídio em si e seu uso
|
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
DK2663548T3
(en)
|
2011-01-11 |
2017-07-24 |
Alnylam Pharmaceuticals Inc |
PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY
|
|
WO2012109162A1
(en)
|
2011-02-07 |
2012-08-16 |
Cerenis Therapeutics Holding S.A. |
Lipoprotein complexes and manufacturing and uses thereof
|
|
WO2012119007A1
(en)
|
2011-03-01 |
2012-09-07 |
N21 Acquisition Holding, Llc |
Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
|
|
JP6250543B2
(ja)
|
2011-09-27 |
2017-12-20 |
アルニラム・ファーマシューティカルズ・インコーポレーテッド |
ジ脂肪族置換ｐｅｇ化脂質
|
|
AU2012352480A1
(en)
|
2011-12-12 |
2014-07-17 |
Melior Pharmaceuticals I, Inc. |
Treatment of type I and type II diabetes
|
|
CN103073646A
(zh)
*
|
2012-03-13 |
2013-05-01 |
华中科技大学 |
一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
|
|
EP2983687B1
(en)
|
2013-03-15 |
2019-09-04 |
The Regents of The University of California |
Peptides having reduced toxicity that stimulate cholesterol efflux
|
|
EP2853259A1
(en)
|
2013-09-30 |
2015-04-01 |
Université Pierre et Marie Curie (Paris 6) |
Reconstituted high density lipoproteins composition and uses thereof
|
|
CN106488987A
(zh)
|
2014-05-02 |
2017-03-08 |
塞勒尼斯医疗控股公司 |
Hdl疗法标志物
|
|
WO2016011049A2
(en)
*
|
2014-07-14 |
2016-01-21 |
Schwendeman Anna |
Compositions and methods for disease treatment using nanoparticle delivered compounds
|
|
EP3189069B1
(en)
|
2014-07-31 |
2024-10-23 |
UAB Research Foundation |
Apoe mimetic peptides and higher potency to clear plasma cholesterol
|
|
US10307491B2
(en)
|
2015-01-30 |
2019-06-04 |
The Regents Of The University Of Michigan |
Liposomal particles comprising biological molecules and uses thereof
|
|
KR102370582B1
(ko)
|
2015-03-13 |
2022-03-04 |
에스페리온 테라피유틱스 인코포레이티드 |
Ｅｔｃ1002 및 에제티미브를 포함하는 고정 용량 조합 및 제형 및 심혈관 질환의 치료 또는 이의 위험의 감소 방법
|
|
MA41793A
(fr)
|
2015-03-16 |
2018-01-23 |
Esperion Therapeutics Inc |
Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
|
|
JP2018516847A
(ja)
|
2015-03-25 |
2018-06-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
生体高分子薬を送達するための組成物及び方法
|
|
CN109069532A
(zh)
|
2016-02-11 |
2018-12-21 |
营养21有限责任公司 |
含铬组合物用于改善健康和健身
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
CN110785170B
(zh)
|
2017-04-10 |
2023-03-28 |
梅里奥尔医药I公司 |
脂肪细胞的治疗
|
|
ES2984285T3
(es)
|
2017-08-10 |
2024-10-29 |
Abionyx Pharma Sa |
Cargómeros
|
|
ES3020757T3
(en)
|
2017-11-22 |
2025-05-23 |
Hdl Therapeutics Inc |
Methods for priming fluid circuits of a plasma processing system
|
|
EP3731814A4
(en)
|
2017-12-28 |
2021-09-29 |
HDL Therapeutics, Inc. |
METHOD OF PRESERVATION AND ADMINISTRATION OF HIGH DENSITY PRE-BETA LIPOPROTEIN EXTRACTED FROM HUMAN PLASMA
|
|
CN115429784A
(zh)
|
2019-06-21 |
2022-12-06 |
艾斯柏伦治疗公司 |
制备贝派地酸及其组合物的方法
|
|
WO2021209823A1
(en)
|
2020-04-16 |
2021-10-21 |
Abionyx Pharma Sa |
Methods for treating acute conditions using lipid binding protein- based complexes
|
|
CA3197168A1
(en)
|
2020-10-01 |
2022-04-07 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
CA3195531A1
(en)
*
|
2020-10-16 |
2022-04-21 |
Aniruddh PANDIT |
Microbiome-derived gaseous sample collection system and methods
|
|
MX2023012223A
(es)
|
2021-04-15 |
2023-10-26 |
Abionyx Pharma Sa |
Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
|
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
|
CN119317440A
(zh)
|
2022-04-06 |
2025-01-14 |
阿比奥尼克斯制药公司 |
使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
|
|
CA3258787A1
(en)
|
2022-06-10 |
2023-12-14 |
Stanislas FAGUER |
METHODS OF TREATMENT OF HYPERINFLAMMATORY DISEASES USING LIPID-BINDING PROTEIN COMPLEXES
|
|
IL317446A
(en)
|
2022-06-10 |
2025-02-01 |
Abionyx Pharma Sa |
Methods for treating acute conditions using complexes based on lipid-binding proteins
|
|
AU2024207875A1
(en)
|
2023-01-13 |
2025-07-24 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|
|
WO2025093929A1
(en)
|
2023-10-31 |
2025-05-08 |
Abionyx Pharma Sa |
Lipid binding protein molecule therapy
|